The Global Tribune

Irritable Bowel Syndrome (IBS) Market Insights, Epidemiology and Competitive Analysis Report 2030

 Breaking News
  • No posts were found

Irritable Bowel Syndrome (IBS) Market Insights, Epidemiology and Competitive Analysis Report 2030

February 24
07:06 2021
Irritable Bowel Syndrome (IBS) Market Insights, Epidemiology and Competitive Analysis Report 2030

DelveInsight Business Research LLP
DelveInsight’s “Irritable Bowel Syndrome (IBS) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Irritable Bowel Syndrome (IBS), historical and forecasted epidemiology as well as the Irritable Bowel Syndrome (IBS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight launched a new report on Irritable Bowel Syndrome (IBS) Market Insights, Epidemiology, and Market Insight 2030.

DelveInsight’s “Irritable Bowel Syndrome (IBS) Market report 2030” delivers an in-depth understanding of the Irritable Bowel Syndrome (IBS), historical and forecasted epidemiology as well as the Irritable Bowel Syndrome (IBS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Irritable Bowel Syndrome (IBS), also known as spastic colon, irritable colon, mucous colitis, and spastic colitis, is a long-term digestive system condition, which causes cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. The symptoms can vary in severity and duration from person to person. However, they last at least three months for at least three days per month. IBS can cause intestinal damage in some cases. The condition is separate from inflammatory bowel disease and isn’t related to other bowel conditions.

Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-market

Irritable Bowel Syndrome Epidemiology Insights:

1. Irritable bowel syndrome (IBS) is the most common functional gastrointestinal (GI) disorder with worldwide prevalence rates ranging generally in the area of 10–15%.

2. Among patients, about 40% of them have mild IBS, 35% suffer from moderate IBS, and 25% from severe IBS.

3. According to DelveInsight’s estimates, the total diagnosed prevalence of IBS in 7MM was found to be 101.5 Million in 2017

Key pharma players involved:

1. Redhill Bio

2. Ardelyx Inc.

Click here and get access to a free sample copy of our report.

Table of contents

1 Key Insight
2 Executive Summary of Irritable Bowel Syndrome
3 Irritable Bowel Syndrome Market Overview at a Glance
4 Disease Background and Overview: Irritable Bowel Syndrome
5 Case Reports
6 Irritable Bowel Syndrome Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Irritable Bowel Syndrome Treatment and Medical Practices
11 Unmet needs
12 Irritable Bowel Syndrome Marketed Drugs
13 Irritable Bowel Syndrome Emerging Drugs
14 Irritable Bowel Syndrome 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Irritable Bowel Syndrome Market Drivers
19 Irritable Bowel Syndrome Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight

Download report: https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-market

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/